# Oncolytic alphavirus replicons mediated recruitment and activation of T cells

**Authors:** Darshak K. Bhatt, Saskia L. Meuleman, Baukje Nynke Hoogeboom, Toos Daemen

PMC · DOI: 10.1016/j.isci.2024.109253 · 2024-02-16

## TL;DR

This paper shows that alphavirus-based replicons can boost immune responses in tumors, especially when encoding cytokines like IFN-γ, even in less responsive cancer cells.

## Contribution

The study introduces cytokine-encoding alphavirus replicons that enhance tumor immunogenicity across different cancer cell types.

## Key findings

- rSFV replicons effectively express transgenes in both tumor monolayer and spheroid models.
- Cytokine-encoding replicons, especially IFN-γ, enhance immune responses regardless of cancer cell susceptibility.
- LNCaP cells show higher infection rates and immune activation compared to PANC-1 cells.

## Abstract

Oncolytic viruses show promise in enhancing tumor immunogenicity by releasing immunogenic signals during tumor cell infection and lysis. In this study, we improved the virus-induced tumor immunogenicity of recombinant Semliki Forest virus (rSFV)-based replicon particles by encoding immunogenic cytokines such as C-X-C motif chemokine ligand 10 (CXCL10), FMS-like tyrosine kinase 3 ligand (Flt3L), or interferon-gamma (IFN-ƴ). Real-time imaging and flow cytometry of human cancer cell-based monolayer and spheroid cultures, using LNCaP or PANC-1 cells, revealed effective infection and transgene expression in both models. LNCaP cells exhibited higher and earlier rSFV infection compared to PANC-1 cells. While infected LNCaP cells effectively triggered immune recruitment and T cell activation even without encoding cytokines, PANC-1 cells demonstrated improved immune responses only when infected with replicons encoding cytokines, particularly IFN-ƴ, which enhanced tumor immunogenicity irrespective of cancer cell susceptibility to infection. Our study demonstrates that despite innate phenotypic disparities in cancer cells, rSFV-based replicons encoding cytokines can potentially generate effective immune responses in the tumor.

•rSFV-replicons effectively express transgenes in tumor monolayer and spheroids•rSFV-replicons can induce transgene-independent immune recruitment and activation•Innate disparities in antiviral response influence immune activation by tumor cells•rSFV-replicons encoding cytokines enhance immune responses across tumor types

rSFV-replicons effectively express transgenes in tumor monolayer and spheroids

rSFV-replicons can induce transgene-independent immune recruitment and activation

Innate disparities in antiviral response influence immune activation by tumor cells

rSFV-replicons encoding cytokines enhance immune responses across tumor types

Immunology; Virology

## Linked entities

- **Genes:** CXCL10 (C-X-C motif chemokine ligand 10) [NCBI Gene 3627], FLT3LG (fms related receptor tyrosine kinase 3 ligand) [NCBI Gene 2323], IFNG (interferon gamma) [NCBI Gene 3458]

## Full-text entities

- **Genes:** IFNG (interferon gamma) [NCBI Gene 3458] {aka IFG, IFI, IMD69}, CXCL10 (C-X-C motif chemokine ligand 10) [NCBI Gene 3627] {aka C7, IFI10, INP10, IP-10, SCYB10, crg-2}, FLT3LG (fms related receptor tyrosine kinase 3 ligand) [NCBI Gene 2323] {aka FL, FLG3L, FLT3L, IMD125}
- **Diseases:** infection (MESH:D007239), cancer (MESH:D009369)
- **Species:** Homo sapiens (human, species) [taxon 9606], Semliki Forest virus (no rank) [taxon 11033]
- **Cell lines:** LNCaP — Homo sapiens (Human), Prostate carcinoma, Cancer cell line (CVCL_0395), PANC-1 — Homo sapiens (Human), Pancreatic ductal adenocarcinoma, Cancer cell line (CVCL_0480)

## Figures

7 figures with captions in the complete paper: https://tomesphere.com/paper/PMC10904282/full.md

---
Source: https://tomesphere.com/paper/PMC10904282